G-CSF augments the neuroprotective effect of conditioned medium of dental pulp stem cells against hypoxic neural injury in SH-SY5Y cells

Document Type : Original Article


1 Medical Toxicology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

2 Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

3 Department of Pharmaceutical Nanotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

4 Department of Medical Genetics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

5 Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran

6 Targeted Drug Delivery Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran


Objective(s): Dental pulp stem cells (DPSCs) can differentiate into functional neurons and have the potential for cell therapy in neurological diseases. Granulocyte colony-stimulating factor (G-CSF) is a glycoprotein family shown neuroprotective effect in models of nerve damage.
we evaluated the protective effects of G-CSF, conditioned media from DPSCs (DPSCs-CM) and conditioned media from transfected DPSCs with plasmid encoding G-CSF (DPSC-CMT) on SH-SY5Y exposed to CoCl2 as a model of hypoxia-induced neural damage.
Materials and Methods: SH-SY5Y exposed to CoCl2 were treated with DPSCs-CM, G-CSF, simultaneous combination of DPSCs-CM and G-CSF and finally DPSC-CMT. Cell viability and apoptosis were determined by resazurin (or lactate dehydrogenase (LDH) assay alternatively) and propidium iodide (PI) staining. Western blot analysis was performed to detect changes in apoptotic protein levels. The interleukin-6 and interleukin-10 IL6/IL10 levels were measured with Enzyme-Linked Immunosorbent Assay (ELISA).
Results: DPSCs-CM and G-CSF were able to significantly protect SH-SY5Y against neural cell damage caused by CoCl2 according to resazurin and LDH analysis. Also, the percentage of apoptotic cells decreased when SH-SY5Y were treated with DPSCs-CM and G-CSF simultaneously. After transfection of DPSCs with G-CSF plasmid, DPSC-CMT could significantly improve the protection. The amount of β-catenin, cleaved PARP and caspase-3 were significantly decreased and the expression of survivin was considerably increased when hypoxic SH-SY5Y treated with DPSCs-CM plus G-CSF according to Western blot. Decreased level of IL-6/IL-10, which exposed to CoCl2, after treatment with DPSCs-CM indicated the suppression of inflammatory mediators.
Conclusion: Combination therapy of G-CSF and DPSCs-CM improved the protective activity.


1. Volkman R, Offen D. Concise review: Mesenchymal stem cells in neurodegenerative diseases. Stem Cells 2017; 35:1867-1880.
2. Mead B, Logan A, Berry M, Leadbeater W, Scheven BA. Concise review: Dental pulp stem cells: a novel cell therapy for retinal and central nervous system repair. Stem Cells 2017; 35:61-67.
3. Yamada Y, Nakamura-Yamada S, Kusano K, Baba S. Clinical potential and current progress of dental pulp stem cells for various systemic diseases in regenerative medicine: A concise review. Int J Mol Sci 2019; 20:1132.
4. Luo L, He Y, Wang X, Key B, Lee BH, Li H, et al. Potential roles of dental pulp stem cells in neural regeneration and repair. Stem Cells Int 2018; 7;2018.
5. Mohan SP, Ramalingam M. Dental pulp stem cells in neuroregeneration. J Pharm Bioallied Sci 2020; 12:S60-S66.
6. Nuti N, Corallo C, Chan B, Ferrari M, Gerami-Naini B. Multipotent differentiation of human dental pulp stem cells: A literature review. Stem Cell Rev Rep 2016; 12:511-523.
7. Hayashi Y, Murakami M, Kawamura R, Ishizaka R, Fukuta O, Nakashima M. CXCL14 and MCP1 are potent trophic factors associated with cell migration and angiogenesis leading to higher regenerative potential of dental pulp side population cells. Stem Cell Res Ther 2015; 6:111.
8. Lan X, Sun Z, Chu C, Boltze J, Li S. Dental pulp stem cells: An attractive alternative for cell therapy in ischemic stroke. Front Neurol 2019; 10:824.
9. Ahmed NE-MB, Murakami M, Hirose Y, Nakashima M. Therapeutic potential of dental pulp stem cell secretome for Alzheimer’s disease treatment: An in vitro study. Stem Cells Int 2016; 2016:8102478.
10. Wang J, Zuzzio K, Walker CL. Systemic dental pulp stem cell secretome therapy in a mouse model of amyotrophic lateral sclerosis. Brain Sci 2019; 9: 165.
11. Frank T, Schlachetzki JC, Göricke B, Meuer K, Rohde G, Dietz GP, et al. Both systemic and local application of granulocyte-colony stimulating factor (G-CSF) is neuroprotective after retinal ganglion cell axotomy. BMC Neurosci 2009; 10-49.
12. Frampton JE, Lee CR, Faulds D. Filgrastim. Drugs 1994; 48:731-760.
13. Tsai S-T, Chu S-C, Liu S-H, Pang C-Y, Hou T-W, Lin S-Z, et al. Neuroprotection of granulocyte colony-stimulating factor for early stage Parkinson’s disease. Cell Transplant 2017; 26:409-416.
14. Liu P-K, Wen Y-T, Lin W, Kapupara K, Tai M, Tsai R-K. Neuroprotective effects of low-dose G-CSF plus meloxicam in a rat model of anterior ischemic optic neuropathy. Sci Rep 2020; 10:1-10.
15. Yanqing Z, Yu-Min L, Jian Q, Bao-Guo X, Chuan-Zhen L. Fibronectin and neuroprotective effect of granulocyte colony-stimulating factor in focal cerebral ischemia. Brain Res 2006; 1098:161-169.
16. Meuer K, Pitzer C, Teismann P, Krüger C, Göricke B, Laage R, et al. Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson’s disease. J Neurochem 2006; 97:675-686.
17. Kichenbrand C, Velot E, Menu P, Moby V. Dental pulp stem cell-derived conditioned medium: An attractive alternative for regenerative therapy. Tissue Eng Part B Rev 2019; 25:78-88.
18.  Pourgonabadi S, Ghorbani A, Tayarani-Najaran Z, Mousavi S.H. In vitro assessment of alendronate toxic and apoptotic  effects on human dental pulp stem cells.  Iran J Basic Med Sci 2018;21:905-910.
19. Pilbauerova N, Soukup T, Kleplova TS, Suchanek J. Enzymatic isolation, amplification and characterization of dental pulp stem cells. Folia Biologica 2019; 65:124-133.
20. Feng J, Wang W. Hypoxia pretreatment and EPO-modification enhance the protective effects of MSC on neuron-like PC12 cells in a similar way. Biochem Biophys Res Commun 2017; 482:232-238.
21. Johnson TV, DeKorver NW, Levasseur VA, Osborne A, Tassoni A, Lorber B, et al. Identification of retinal ganglion cell neuroprotection conferred by platelet-derived growth factor through analysis of the mesenchymal stem cell secretome. Brain 2014; 137:503-519.
22. Salmasi Z, Hashemi M, Mahdipour E, Nourani H, Abnous K, Ramezani M. Mesenchymal stem cells engineered by modified polyethylenimine polymer for targeted cancer gene therapy, in vitro and in vivo. Biotechnol Prog 2020; 36:e3025.
23. Mead B, Logan A, Berry M, Leadbeater W, Scheven BA. Intravitreally transplanted dental pulp stem cells promote neuroprotection and axon regeneration of retinal ganglion cells after optic nerve injury. Invest Ophthalmol Vis Sci 2013; 54:7544-7556.
24. Ledesma-Martínez E, Mendoza-Núñez VM, Santiago-Osorio E. Mesenchymal stem cells derived from dental pulp: A review. Stem Cells Int 2016; 2016:4709572.
25. Sowa K, Nito C, Nakajima M, Suda S, Nishiyama Y, Sakamoto Y, et al. Impact of dental pulp stem cells overexpressing hepatocyte growth factor after cerebral ischemia/reperfusion in rats. Mol Ther Methods Clin Dev 2018; 10:281-290.
26. Leong WK, Henshall TL, Arthur A, Kremer KL, Lewis MD, Helps SC, et al. Human adult dental pulp stem cells enhance poststroke functional recovery through non-neural replacement mechanisms. Stem Cells Transl Med 2012; 1:177-187.
27. Biedler JL, Helson L, Spengler BA. Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res 1973; 33:2643-2652.
28. Cantinieaux D, Quertainmont R, Blacher S, Rossi L, Wanet T, Noël A, et al. Conditioned medium from bone marrow-derived mesenchymal stem cells improves recovery after spinal cord injury in rats: An original strategy to avoid cell transplantation. PLoS One 2013; 8: e69515.
29. Chang C-P, Chio C-C, Cheong C-U, Chao C-M, Cheng B-C, Lin M-T. Hypoxic preconditioning enhances the therapeutic potential of the secretome from cultured human mesenchymal stem cells in experimental traumatic brain injury. Clin Sci 2013; 124:165-176.
30. Katagiri W, Osugi M, Kinoshita K, Hibi H. Conditioned medium from mesenchymal stem cells enhances early bone regeneration after maxillary sinus floor elevation in rabbits. Implant Dent 2015; 24:657-663.
31. Timmers L, Lim SK, Hoefer IE, Arslan F, Lai RC, van Oorschot AA, et al. Human mesenchymal stem cell-conditioned medium improves cardiac function following myocardial infarction. Stem Cell Res 2011; 6:206-214.
32. Ghahari L, Safari M, Joghataei MT, Mehdizadeh M, Soleimani M. Effect of combination therapy using hypothermia and granulocyte colony-stimulating factor in a rat transient middle cerebral artery occlusion model. Iran Biomed J 2014; 18:239-244.
33. Zhao LR, Singhal S, Duan WM, Mehta J, Kessler JA. Brain repair by hematopoietic growth factors in a rat model of stroke. Stroke 2007; 38:2584-2591.
34. Schneider A, Krüger C, Steigleder T, Weber D, Pitzer C, Laage R, et al. The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest 2005; 115:2083-2098.
35. Shyu WC, Lin SZ, Lee CC, Liu DD, Li H. Granulocyte colony-stimulating factor for acute ischemic stroke: A randomized controlled trial. CMAJ 2006; 174:927-933.
36. Solaroglu I, Cahill J, Tsubokawa T, Beskonakli E, Zhang JH. Granulocyte colony-stimulating factor protects the brain against experimental stroke via inhibition of apoptosis and inflammation. Neurol Res 2009; 31:167-172.
37. Fathali N, Lekic T, Zhang JH, Tang J. Long-term evaluation of granulocyte-colony stimulating factor on hypoxic-ischemic brain damage in infant rats. Intensive Care Med 2010; 36:1602-1608.
38. Gibson CL, Jones NC, Prior MJ, Bath PM, Murphy SP. G-CSF suppresses edema formation and reduces interleukin-1β expression after cerebral ischemia in mice. J Neuropathol Exp Neurol 2005; 64:763-769.
39. Zhang X-M, Du F, Yang D, Wang R, Yu C-J, Huang X-N, et al. Granulocyte colony-stimulating factor increases the therapeutic efficacy of bone marrow mononuclear cell transplantation in cerebral ischemia in mice. BMC Neurosci 2011; 12:61.
40. Balseanu AT, Buga A-M, Catalin B, Wagner D-C, Boltze J, Zagrean A-M, et al. Multimodal approaches for regenerative stroke therapies: combination of granulocyte colony-stimulating factor with bone marrow mesenchymal stem cells is not superior to G-CSF alone. Front Aging Neurosci 2014; 6:130.
41. Acosta SA, Tajiri N, Shinozuka K, Ishikawa H, Sanberg PR, Sanchez-Ramos J, et al. Combination therapy of human umbilical cord blood cells and granulocyte colony stimulating factor reduces histopathological and motor impairments in an experimental model of chronic traumatic brain injury. PLoS One 2014; 9:e90953.
42. Huang C, Fu X-H, Zhou D, Li J-M. The role of Wnt/β-catenin signaling pathway in disrupted hippocampal neurogenesis of temporal lobe epilepsy: A potential therapeutic target? Neurochem Res 2015; 40:1319-1332.
43. Sun F-L, Wang W, Zuo W, Xue J-L, Xu J-d, Ai H-X, et al. Promoting neurogenesis via Wnt/β-catenin signaling pathway accounts for the neurorestorative effects of morroniside against cerebral ischemia injury. Eur J Pharmacol 2014; 738:214-221.
44. Lei Z-N, Liu F, Zhang L-M, Huang Y-L, Sun F-Y. Bcl-2 increases stroke-induced striatal neurogenesis in adult brains by inhibiting BMP-4 function via activation of β-catenin signaling. Neurochem Int 2012; 61:34-42.
45. Lovestone S, Killick R, Di Forti M, Murray R. Schizophrenia as a GSK-3 dysregulation disorder. Trends Neurosci 2007; 30:142-149.
46. Inestrosa N, Tapia-Rojas C, Griffith T, Carvajal F, Benito M, Rivera-Dictter A, et al. Tetrahydrohyperforin prevents cognitive deficit, Aβ deposition, tau phosphorylation and synaptotoxicity in the APPswe/PSEN1ΔE9 model of Alzheimer’s disease: a possible effect on APP processing. Transl Psychiatry 2011; 1:e20.
47. Damalas A, Ben-Ze’ev A, Simcha I, Shtutman M, Leal JFM, Zhurinsky J, et al. Excess β-catenin promotes accumulation of transcriptionally active p53. EMBO J 1999; 18:3054-3063.
48. Zalvide J, DeCaprio JA. Role of pRb-related proteins in simian virus 40 large-T-antigen-mediated transformation. Mol Cell Biol 1995; 15:5800-5810.
49. Pećina-Šlaus N. Wnt signal transduction pathway and apoptosis: A review. Cancer Cell Int 2010; 10:1-5.
50. Albadawi H, Crawford RS, Atkins MD, Watkins MT. Role of poly(ADP-ribose) polymerase during vascular reconstruction. Vascular 2006; 14:362-365.
51. Chaitanya GV, Alexander JS, Babu PP. PARP-1 cleavage fragments: Signatures of cell-death proteases in neurodegeneration. Cell Commun Signal 2010; 8:1-11.
52. Altieri DC. Survivin and apoptosis control. Adv Cancer Res 2003; 88:31-52.
53. Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood 1995; 86:1243-1254.
54. Erta M, Quintana A, Hidalgo J. Interleukin-6, a major cytokine in the central nervous system. Int J Biol Sci 2012; 8:1254-1266.
55. Huang J, Upadhyay UM, Tamargo RJ. Inflammation in stroke and focal cerebral ischemia. Surg Neurol 2006; 66:232-245.
56. Swartz KR, Liu F, Sewell D, Schochet T, Campbell I, Sandor M, et al. Interleukin-6 promotes post-traumatic healing in the central nervous system. Brain Res 2001; 896:86-95.
57. Gu Y, He M, Zhou X, Liu J, Hou N, Bin T, et al. Endogenous IL-6 of mesenchymal stem cell improves behavioral outcome of hypoxic-ischemic brain damage neonatal rats by supressing apoptosis in astrocyte. Sci Rep 2016; 6:1-16.
58. Mosser DM, Zhang X. Interleukin-10: New perspectives on an old cytokine. Immunol Rev 2008; 226:205-218.
59. Garcia JM, Stillings SA, Leclerc JL, Phillips H, Edwards NJ, Robicsek SA, et al. Role of interleukin-10 in acute brain injuries. Front Neurol 2017; 8:244.
60. Porro C, Cianciulli A, Panaro MA. The regulatory role of il-10 in neurodegenerative diseases. Biomolecules 2020; 10:1017.